Roivant SciencesROIV +1.56%55 Buyback Yield % is 0.51 as of Jun. 29, 2026, which is 75% below its 10-year median of 2.01. GuruFocus rates ROIV with a GF Score™ of 55/100 and a GF Value™ of $10.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 742 Biotechnology companies, Roivant Sciences ranks better than 91.37% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Roivant Sciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROIV vs RPRX, BNTX, INCY: Buyback Yield % Comparison
For the Biotechnology subindustry, Roivant Sciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIV) has a Buyback Yield % of 0.51 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Roivant Sciences and its competitors. This is 75% below median its historical median of 2.01. According to the industry distribution chart, Roivant Sciences ranks #64 out of 742 companies in the Biotechnology industry, placing it in the top 8.6%.
Is Roivant Sciences' Buyback Yield % too high?
Roivant Sciences' current Buyback Yield % of 0.51 is 75% below median its 10-year median of 2.01. Based on the distribution chart, Roivant Sciences ranks #64 out of 742 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Buyback Yield % compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #64 out of 742 companies for Buyback Yield %. This places Roivant Sciences in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Buyback Yield % is 0.51, which is 75% below median its own 10-year median of 2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.45, compared to a current price of $34.60 — trading 231.1% above its estimated fair value. The current Buyback Yield % is 0.51, which is 75% below median its 10-year median of 2.01. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Buyback Yield % is 0.51 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $34.60 is trading 231.1% above its estimated GF Value™ of $10.45.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
Buyback Yield %: 0.51 (75% below median its 10-year median of 2.01)
GF Value™: $10.45 vs. price of $34.60 (231.1% above fair value)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score
Get the complete analysis for ROIV
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 
